$1.11
Today
as of Sep 4, 16:52 ET
Last 30 days
Recent Press Releases & News
NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak
NanoViricides Raises Financing for Trial of Ebola Treatment, Awaits Regulatory Approval in Congo
NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial
Overview
52-week range
$0.85
$2.23
19% of range
Avg surprise (last 0)
—
Avg reaction (last 2)
+2.6%
100% positive
Latest IV / EM
1557%
EM ±243.2% · $3 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 14, 2026 | Mar/2026 | $-0.09 | — | — | +35.7% | +1.2% | earnings |
| Wed Dec 31, 2025 | Dec 2025 | $-0.11 | — | — | — | — | financials |
| Mon Sep 29, 2025 | Jun/2025 | $-0.13 | — | — | — | — | earnings |
| Thu May 15, 2025 | Mar/2025 | $-0.14 | — | — | — | +4.0% | earnings |
| Tue Dec 31, 2024 | Dec 2024 | $-0.14 | — | — | — | — | financials |
| Mon Sep 30, 2024 | Sep 2024 | $-0.23 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.16 | — | — | — | — | financials |
| Sun Dec 31, 2023 | Dec 2023 | $-0.18 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.17 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.15 | — | — | — | — | financials |
| Sat Dec 31, 2022 | Dec 2022 | $-0.15 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | — | — | — | $0 | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-2M | $-2M | $-2M | — | $-2M | $-2M | $-3M | — |
| Net income | $-2M | $-2M | $-2M | — | $-2M | $-2M | $-3M | — |
| EPS (diluted) | $-0.09 | $-0.11 | $-0.10 | — | $-0.14 | $-0.14 | $-0.23 | — |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $3M | $5M | $1M | $2M | $3M | $4M | $4M | $5M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $3M | $5M | $1M | $2M | $3M | $4M | $4M | $5M |
| Total assets | $10M | $12M | $8M | $9M | $10M | $12M | $12M | $13M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $1M | $1M | $1M | — | — | $1M | $2M | — |
| Total equity | $9M | $11M | $7M | $8M | $9M | $10M | $10M | $11M |